Compare SCWO & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCWO | SER |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 42.0M |
| IPO Year | 2022 | 2024 |
| Metric | SCWO | SER |
|---|---|---|
| Price | $2.44 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 52.3K | ★ 54.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $215,037.00 | $130,000.00 |
| Revenue This Year | $25,798.80 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $0.19 | $1.22 |
| 52 Week High | $3.60 | $7.92 |
| Indicator | SCWO | SER |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 63.48 |
| Support Level | $2.35 | $1.69 |
| Resistance Level | $2.81 | $3.16 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 50.82 | 78.75 |
374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.